Trial Profile
A Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults With Mobility Limitations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2017
Price :
$35
*
At a glance
- Drugs Bimagrumab (Primary)
- Indications Mobility limitation; Muscular atrophy
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 02 May 2014 New trial record